Louis M Sloan

Title: Louis M. Sloan: Innovator in Dendritic Cell Vaccines

Introduction

Louis M. Sloan is a notable inventor based in Dallas, TX (US), recognized for his contributions to the field of immunology. He has developed innovative solutions aimed at combating human immunodeficiency virus (HIV) infections through advanced vaccine technologies. His work has significant implications for the treatment and prevention of HIV.

Latest Patents

Sloan holds a patent for his invention titled "Dendritic cell vaccines - Compositions and methods for the prophylaxis and treatment of human immunodeficiency virus (HIV) infections." This patent describes an autologous dendritic cell (DC) vaccine product derived by culturing a patient's monocytes with granulocyte macrophage colony stimulating factor (GM-CSF) and interferon alpha 2b (IFN-α). The vaccine is loaded with a mixture of five lipopeptides of Gag, Nef, and Pol HIV antigens, and may also involve the activation of the DC with lipopolysaccharide (LPS). This innovative approach represents a significant advancement in HIV treatment.

Career Highlights

Throughout his career, Louis M. Sloan has worked with esteemed organizations such as Baylor Research Institute and Agence Nationale De Recherches Sur Le Sida Et Les Hepatitis Virales. His experience in these institutions has allowed him to contribute to groundbreaking research in the field of HIV and immunotherapy.

Collaborations

Sloan has collaborated with notable professionals in the field, including Jacques F. Banchereau and Monica Montes. These partnerships have further enhanced the impact of his research and innovations.

Conclusion

Louis M. Sloan's work in developing dendritic cell vaccines showcases his commitment to advancing medical science and improving treatment options for HIV. His innovative approaches and collaborations have positioned him as a key figure in the field of immunology.